Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
2.
Eur J Clin Microbiol Infect Dis ; 36(3): 487-494, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27787664

RESUMEN

In April 2015, the Spanish National Health System (SNHS) developed a national strategic plan for the diagnosis, treatment, and management of hepatitis C virus (HCV). Our aim was to analyze the impact of this on human immunodeficiency virus (HIV)-infected patients included in the HERACLES cohort during the first 6 months of its implementation. The HERACLES cohort (NCT02511496) was set up in March 2015 to evaluate the status and follow-up of chronic HCV infection in patients co-infected with HIV in the south of Spain. In September 2015, the data were analyzed to identify clinical events (death, liver decompensation, and liver fibrosis progression) and rate of treatment implementation in this population. The study population comprised a total of 3474 HIV/HCV co-infected patients. The distribution according to liver fibrosis stage was: 1152 F0-F1 (33.2 %); 513 F2 (14.4 %); 641 F3 (18.2 %); 761 F4 (21.9 %); and 407 whose liver fibrosis was not measured (12.3 %). During follow-up, 248 patients progressed by at least one fibrosis stage [7.1 %; 95 % confidence interval (CI): 6.3-8 %]. Among cirrhotic patients, 52 (6.8 %; 95 % CI: 5.2-8.9 %) developed hepatic decompensation. In the overall population, 50 patients died (1.4 %; 95 % CI: 1.1-1.9 %). Eight hundred and nineteen patients (23.56 %) initiated interferon (IFN)-free treatment during follow-up, of which 47.8 % were cirrhotic. In our study, during 6 months of follow-up, 23.56 % of HIV/HCV co-infected patients included in our cohort received HCV treatment. However, we observed a high incidence of negative short-term outcomes in our population.


Asunto(s)
Antivirales/uso terapéutico , Infecciones por VIH/complicaciones , Accesibilidad a los Servicios de Salud , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/tratamiento farmacológico , Cirrosis Hepática/epidemiología , Fallo Hepático/epidemiología , Adulto , Anciano , Femenino , Política de Salud , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/mortalidad , Humanos , Cirrosis Hepática/patología , Fallo Hepático/patología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , España , Análisis de Supervivencia , Resultado del Tratamiento
3.
Eur J Clin Microbiol Infect Dis ; 34(11): 2247-55, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26342330

RESUMEN

The implementation of hepatitis C (HCV) direct-acting antiviral drugs is prioritized in several populations in which its application provides the most immediate and impactful benefit. In this scenario, a precise knowledge of the situation of human immunodeficiency virus (HIV)/HCV chronic co-infection is required to adequately address this disease. This cross-sectional study was performed in 21 hospitals in Andalusia (Spain). The study population consisted of HIV-infected patients with an active HCV chronic infection who were not receiving HCV treatment at the time of inclusion. A total of 13,506 HIV-infected patients were included in the study. Of them, 2561 (18.9 %) presented chronic HCV infection. The majority of the patients included were on highly active antiretroviral therapy (HAART; 96.2 %), showed plasma levels with an undetectable HIV viral load (92.5 %), and had a good immunological status (median CD4+ cell count of 486 cells/mL). The HCV genotype distribution was as follows: 58.1 % were genotype 1, 1.1 % were genotype 2, 16.1 % were genotype 3, and 22.1 % were genotype 4 (2.6 % were missing data). In total, 24.8 % of the patients showed liver fibrosis stage F0-F1, 27.9 % showed stage F2, 16.7 % showed stage F3, and 21 % showed stage F4 (9.6 % were missing data). With regards to previous HCV treatment experiences, 68.05 % of the patients were naïve and 31.95 % had failed to respond to a previous treatment. The burden of HCV/HIV co-infected patients in our population was reported as one in five HIV-infected patients requiring HCV treatment. The implementation of extra resources to face this important health challenge is mandatory.


Asunto(s)
Coinfección/epidemiología , Infecciones por VIH/complicaciones , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/epidemiología , Cirrosis Hepática/epidemiología , Adulto , Coinfección/patología , Estudios Transversales , Femenino , Genotipo , Hepacivirus/clasificación , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Humanos , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , España/epidemiología
4.
Gut ; 58(12): 1654-60, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19625279

RESUMEN

BACKGROUND: The factors that influence liver fibrosis progression in patients co-infected with human immunodeficiency virus/hepatitis C virus (HIV/HCV) are not completely understood. It is not known if insulin resistance (IR), a condition that promotes liver fibrosis in HCV mono-infected individuals, is one of these factors. OBJECTIVE: To evaluate the association between IR and liver stiffness (LS). DESIGN: Multicentre cross-sectional study. PATIENTS: 330 patients co-infected with HIV/HCV. METHODS: LS was assessed by transient elastography, which has shown a high accuracy to predict significant fibrosis in patients co-infected with HIV/HCV. The outcome variable of the study was LS. Patients with LS> or =9 kPa were considered as having significant fibrosis. IR was calculated using the HOMA method. RESULTS: LS was > or =9 kPa in 150 (45%) patients. HOMA correlated with LS (Spearman's rho correlation coefficient, 0.37; p<0.0001). The median (Q1-Q3) HOMA in patients with LS> or =9 kPa was 3.30 (2.17-5.16) while it was 2.09 (1.37-3.22) in patients with LS <9 kPa (p<0.0001). Ninety-six (39%) individuals with a HOMA <4 and 54 (63%) with a HOMA > or =4 showed LS> or =9 kPa (p<0.0001). Analyses after excluding patients with cirrhosis yielded similar results. After multivariate analyses, age > or =40 years (adjusted odds ratio (AOR), 1.85; 95% confidence interval (CI), 1.03 to 3.29; p = 0.03), CD4 cell count <200 cells/ml (AOR, 3.45; 95% CI, 1.67 to 7.11; p = 0.001), hepatitis B virus co-infection (AOR, 9.25; 95% CI, 2.42 to 35.31; p = 0.001), and HOMA > or =4 (AOR, 5.33; 95% CI, 2.70 to 10.49; p<0.0001) were the independent predictors of LS> or =9 kPa. CONCLUSION: IR is associated with LS in patients co-infected with HIV/HCV.


Asunto(s)
Infecciones por VIH/complicaciones , Hepatitis C Crónica/complicaciones , Resistencia a la Insulina , Cirrosis Hepática/virología , Adulto , Estudios Transversales , Progresión de la Enfermedad , Elasticidad , Diagnóstico por Imagen de Elasticidad , Femenino , Infecciones por VIH/diagnóstico por imagen , Infecciones por VIH/fisiopatología , Hepatitis C Crónica/diagnóstico por imagen , Hepatitis C Crónica/fisiopatología , Humanos , Hígado/diagnóstico por imagen , Hígado/fisiopatología , Cirrosis Hepática/diagnóstico por imagen , Cirrosis Hepática/fisiopatología , Masculino , Persona de Mediana Edad
5.
Rev Esp Quimioter ; 30(6): 464-467, 2017 Dec.
Artículo en Español | MEDLINE | ID: mdl-29160649

RESUMEN

OBJECTIVE: Performing of diagnostic test simple using samples not invasive in the diagnosis of visceral leishmaniasis (VL) may be very beneficial, being necessary comparing to traditional methods. The objective of this study was to know the reliability of test KAtex in the urine of patients with suspicion of VL. METHODS: Retrospectively were reviewed the medical histories of patients with suspected of VL to which are performed the test between 2009 and 2015. For its analysis were selected the patients to which is them had made study of the parasite in bone marrow. RESULTS: A total of 110 patients were studied, and bone marrow biopsy for research of Leishmania was performed in 44 (40%). In these patients the sensitivity of the test was 50%, the specificity of 96.7%, positive predictive value of 87.5% and negative predictive value of 80.5%. CONCLUSIONS: KAtex antigenuria sensitivity is too low recommending it as a unique method in the detection of VL in our medium.


Asunto(s)
Pruebas de Fijación de Látex , Leishmaniasis Visceral/diagnóstico , Adulto , Anciano , Antígenos de Protozoos/orina , Biopsia , Médula Ósea/parasitología , Femenino , Hospitales , Humanos , Leishmaniasis Visceral/parasitología , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad
6.
Clin Microbiol Infect ; 22(1): 98.e7-98.e10, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26454060

RESUMEN

Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT.


Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Inhibidores de la Proteasa del VIH/uso terapéutico , VIH-1/aislamiento & purificación , Semen/virología , Esparcimiento de Virus/efectos de los fármacos , Adulto , Estudios Transversales , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
7.
Rev Neurol ; 24(136): 1619-22, 1996 Dec.
Artículo en Español | MEDLINE | ID: mdl-9064187

RESUMEN

The otorhinolaryngological signs of AIDS are reviewed (both analysis and synthesis) following the chronological order of the literature. The earliest clinical pictures, their frequency and time of onset, are described by the authors studied. In 1986 the ENT signs of this disease were well known, and in our region the same multiple, polyfacetic aspects are seen. Personal experience of this is described, emphasizing how seldom the diagnosis has been made, except early on. Usually the cases seen and diagnosed by the Department of Infectious Diseases were referred for specialist opinion. The commonest findings were, amongst the opportunist infections: oropharyngeal and oesophageal candidiasis, and tuberculous adenopathies. Classical ENT pathology was represented by sinusitis and to a lesser extent by otitis and tonsillitis. The tumours seen were non-Hodgkin lymphomas, but no Hodgkin's or Burkitt's lymphomas. There was an unusual case of 'high grade centroblastic lymphoma', localized to the tonsil and presenting as necrotic tonsillitis and peritonsillar abscess. Recently a patient with a large pharyngeal tumour (still being investigated) has been provisionally diagnosed as having a cavernous angioma. Both these patients were diagnosed by us, since we saw the first sign of the disease. We have seen few Kaposi's sarcomas, since cutaneous and oral lesions are not usually referred to us.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Tonsila Palatina/microbiología , Tonsila Palatina/virología , Candida/aislamiento & purificación , Humanos , Linfoma no Hodgkin/complicaciones , Orofaringe/virología , Papillomaviridae/aislamiento & purificación , Proteus mirabilis/aislamiento & purificación , Sarcoma de Kaposi/complicaciones
14.
Qual Life Res ; 14(5): 1301-10, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16047505

RESUMEN

OBJECTIVES: This study aims to analyse how a wide group of clinical, social, demographic and psychological factors are related to both physical and mental quality of life in HIV + patients. DESIGN: A cross-sectional study was carried out of 320 HIV + patients in antiretroviral treatment who attended infectious diseases units in four hospitals in the region of Andalusia (Spain). METHODS: Health-Related Quality of Life was measured by the MOS-HIV. Included as independent variables were: sociodemographic variables, variables related to antiretroviral therapy, psychosocial variables like social support (Duke-UNC-11) and psychological morbidity (GHQ-28), variables related to main risk behaviours and clinical variables. RESULTS: In the multiple linear regression analysis, a better PHS quality of life was found to be associated with the absence of mental illness, social support, not being an intravenous drug user and using more than one type of non-injectable drug. A better quality of life, in mental terms, was found to be associated with fewer years as a non-intravenous drug user, having social support, absence of mental illness, not being an intravenous drug user taking only one additional pill, not having any difficulty in taking the medication, and being female. CONCLUSIONS: The study of other non-biological factors that may be related to quality of life has been limited practically to social support and the emotional state. This study highlights the importance of these factors independently from the clinical state, as well as the existence of other psychological and behavioural factors that are also related.


Asunto(s)
Infecciones por VIH/psicología , Calidad de Vida , Perfil de Impacto de Enfermedad , Encuestas y Cuestionarios , Actividades Cotidianas , Adulto , Antirretrovirales , Estudios Transversales , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Salud Mental , Evaluación de Resultado en la Atención de Salud , Factores de Riesgo , Asunción de Riesgos , Factores Sexuales , Apoyo Social , España , Abuso de Sustancias por Vía Intravenosa/complicaciones , Abuso de Sustancias por Vía Intravenosa/psicología
15.
J Clin Microbiol ; 36(2): 520-5, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9466769

RESUMEN

A prospective, multicenter study was carried out over a period of 10 months. All patients with clinically significant bacteremia caused by Enterococcus spp. were included. The epidemiological, microbiological, clinical, and prognostic features and the relationship of these features to the presence of high-level resistance to gentamicin (HLRG) were studied. Ninety-three patients with enterococcal bacteremia were included, and 31 of these cases were caused by HLRG (33%). The multivariate analysis selected chronic renal failure, intensive care unit stay, previous use of antimicrobial agents, and Enterococcus faecalis species as the independent risk factors that influenced the development of HLRG. The strains with HLRG showed lower levels of susceptibility to penicillin and ciprofloxacin. Clinical features (except for chronic renal failure) were similar in both groups of patients. HLRG did not influence the prognosis for patients with enterococcal bacteremia in terms of either the crude mortality rate (29% for patients with bacteremia caused by enterococci with HLRG and 28% for patients not infected with strains with HLRG) or the hospital stay after the acquisition of enterococcal bacteremia. Hemodynamic compromise, inappropriate antimicrobial therapy, and mechanical ventilation were revealed in the multivariate analysis to be the independent risk factors for mortality. Prolonged hospitalization was associated with the nosocomial acquisition of bacteremia and polymicrobial infections.


Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/epidemiología , Enterococcus , Gentamicinas/uso terapéutico , Infecciones por Bacterias Grampositivas/epidemiología , Adulto , Anciano , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Cateterismo/efectos adversos , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/epidemiología , Infección Hospitalaria/microbiología , Farmacorresistencia Microbiana , Enterococcus faecalis , Femenino , Cirugía General , Infecciones por Bacterias Grampositivas/diagnóstico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Hospitalización , Humanos , Unidades de Cuidados Intensivos , Intubación Gastrointestinal/efectos adversos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Nutrición Parenteral/efectos adversos , Pronóstico , Estudios Prospectivos , Insuficiencia Renal/microbiología , Respiración Artificial/efectos adversos , Factores de Riesgo , España/epidemiología
16.
Klin Wochenschr ; 66(24): 1212-3, 1988 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-3236764

RESUMEN

We report three cases (two adult males and a 12-year-old child) of boutonneuse fever produced by inoculation of the conjunctival mucosa (probably through accidental entry of R. conorii fluid into the eyes through rubbing or splashing). All three patients developed similar symptoms of disease, including high fever, headache, maculopapular exanthem, and conjunctivitis, and none had tache noire. Specific immunofluorescent antibodies appeared in these patients' serum mostly after the 2nd week; agglutinins to Proteus OX-19, OX-2 (Weil-Felix reaction) were found. Cure was obtained by oral tetracycline. Conjunctival inoculation of R. conorii producing boutonneuse fever is very rare; this report will probably be one of the first published in the medical literature.


Asunto(s)
Fiebre Botonosa/transmisión , Conjuntiva/microbiología , Conjuntivitis Bacteriana/complicaciones , Adulto , Fiebre Botonosa/microbiología , Niño , Humanos , Masculino , Rickettsia/patogenicidad
17.
Enferm Infecc Microbiol Clin ; 7(7): 349-53, 1989.
Artículo en Español | MEDLINE | ID: mdl-2490459

RESUMEN

A surprise monitoring of plasma aminoglycoside level was carried out in our Hospital in 55 patients. Basal samples and samples one hour after i.m. or i.v. administration were obtained. A protocol sheet with personal, clinical and therapeutic data was filled for each patient. The FPIA analysis technique (CV less than 5%) was used. Only the data related to gentamicin were evaluated, because the number of patients receiving other aminoglycosides was very low (5 cases). The most usual dose and interval were 80 mg (91%) and 12 hours (69%), respectively. The administration routes were i.v. (52%) and i.m. (48%). Blood urea and/or creatinine levels were not measured in 22% of patients. The baseline gentamicin levels were subtherapeutic in 30%, therapeutical in 57%, and toxic in 13%, and 50%, 46% and 4%, respectively, for the levels after one hour. In patients with abnormal renal function a good correlation could be demonstrated (r = 0.96; p less than 0.001) between creatinine level and gentamicin 1/2 time. This correlation was absent in patients with normal renal function. When the dose of the antibiotic was adjusted to the weight of the patient, the frequency of therapeutic levels was higher (47%; p less than 0.03); in these cases, the most common administration interval was 8 hours (p less than 0.01). We emphasize the lack of control of the renal function in 22% of patients, stressing that the lack of monitoring systematically results in potentially subtherapeutic levels in more than one half of the investigated patients (57%).


Asunto(s)
Gentamicinas/farmacocinética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Peso Corporal , Creatinina/sangre , Esquema de Medicación , Gentamicinas/administración & dosificación , Gentamicinas/sangre , Hospitales Generales , Humanos , Infusiones Intravenosas , Inyecciones Intramusculares , Enfermedades Renales/sangre , Tasa de Depuración Metabólica , Persona de Mediana Edad , España
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA